Cleveland Clinic Cancer Advances

De: Cleveland Clinic Taussig Cancer Institute
  • Resumen

  • A Cleveland Clinic podcast for medical professionals exploring the latest innovative research and clinical advances in the field of oncology.
    © 2024 Cleveland Clinic Cancer Advances
    Más Menos
activate_WEBCRO358_DT_T2
Episodios
  • New ASCO Guidelines for Managing Osteoradionecrosis
    Sep 5 2024

    Shlomo Koyfman, MD, Director of Head and Neck and Skin Radiation at Cleveland Clinic, joins the Cancer Advances podcast to talk about the latest ASCO clinical practice guidelines for managing osteoradionecrosis, a potential complication due to radiation therapy. Listen as Dr. Koyfman discuss how the new guidelines are designed to enhance the prevention, early detection, and management of osteoradionecrosis. He shares insights into how these guidelines can be put into practice, and the impact of these new strategies on patient care and survivorship.

    Más Menos
    26 m
  • Tumor-Infiltrating Lymphocyte (TIL) Therapy
    Aug 29 2024

    Thach-Giao Truong, MD, Director of the Melanoma Program at Cleveland Clinic, joins the Cancer Advances podcast to discuss Tumor-Infiltrating Lymphocyte (TIL) therapy. This cutting-edge, personalized cancer treatment utilizes a patient's immune cells to target and destroy tumors. Listen as Dr. Truong provides insights into the science behind TIL therapy, its advantages, and its potential to revolutionize treatment for patients with resistant melanoma and other challenging cancers.

    Más Menos
    19 m
  • Exploring VISTA and LRIG1 Interactions: Cancer Immunotherapy
    Aug 22 2024

    Lily Wang, PhD, from the Department of Translational Hematology Oncology Research at Cleveland Clinic, joins the Cancer Advances Podcast to dive into her research on VISTA and LRIG1 interactions. Dr. Wang, an expert in immune mechanisms within cancer, discusses her lab's innovative work on these immune checkpoint proteins and their potential to overcome current treatment limitations. Discover how targeting the VISTA-LRIG1 axis could offer new strategies for tackling resistant tumors and improving patient outcomes.

    Más Menos
    17 m

Lo que los oyentes dicen sobre Cleveland Clinic Cancer Advances

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.